Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
about
Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditionsCardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloofImplementing guidelines in primary care: can population impact measures help?Hypertension, diabetes and overweight: looming legacies of the Biafran famineESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAssociation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational studyHepatic steatosis: a benign disease or a silent killerDrug-induced diabetes mellitusComparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimatesHomocysteine-lowering interventions for preventing cardiovascular eventsInterventions for deliberately altering blood pressure in acute strokeHomocysteine-lowering interventions for preventing cardiovascular eventsTreatment of hypertension in peripheral arterial diseaseAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseCalcium channel blockers versus other classes of drugs for hypertensionEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraFirst-line drugs for hypertensionTreatment of hypertension in peripheral arterial diseaseInterventions for deliberately altering blood pressure in acute strokeAngiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney diseaseAntioxidant supplements for preventing gastrointestinal cancersAntioxidant supplements for prevention of mortality in healthy participants and patients with various diseasesEarly invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent eraAntioxidant supplements for preventing gastrointestinal cancersHypertension: empirical evidence and implications in 2014Human ACE and bradykinin B2 receptors form a complex at the plasma membraneDevices in the management of advanced, chronic heart failure25-hydroxyvitamin D levels and the risk of mortality in the general populationReporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacyManagement of lower extremity peripheral arterial diseaseEffect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failureIn vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular diseaseIs there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice?Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!Why do antioxidants fail to provide clinical benefit?Debate: Does it matter how you lower blood pressure?Angiotensin receptor blockers in heart failure after the ELITE II trialDebate: does it matter how you lower blood pressure?Dose response of ACE inhibitors: implications of the SECURE trial
P2860
Q21203068-1015E442-9FF3-4A58-9D6D-AC304E34A586Q21246039-2B9F1CE0-8BAB-4841-BF0E-314838194DEBQ21257249-60B58528-4B0E-4415-8172-70EB04A9EED2Q21562156-2C00AEB6-0127-4B16-B9F8-6EB524B41260Q22241786-04F25AF0-E40A-43DB-9217-39D008A819F5Q22242096-99817C8E-547A-48BC-A5E0-0D11EB804A57Q22305506-3E869F88-445C-4350-B20D-7FD1D29866A9Q22306015-947EB17E-970B-446B-A665-3628BD32AD3DQ24186056-2EDA0A9C-A198-4442-AD7C-4FBB90D9F550Q24186605-D392E63B-C205-4257-904A-AD176D706AD3Q24193073-F9D68FCD-2648-49AA-9E26-04A5A79F5C62Q24201783-8B9B8B37-151A-475D-8D2D-431E9B0FA999Q24201969-40889515-C8E7-4BEE-89C9-31A943A6F04EQ24235834-4DB37B8E-B1A3-49C3-ADD5-FC1D292DA27BQ24236584-BFB2584F-4428-4D9E-86BB-134EB40DCBC9Q24236794-C093B952-5808-4210-BEC5-F734DB9C3863Q24239935-0D55D0CC-F0D0-4FF5-A5FF-CE9C8C6D6EBFQ24240538-92467BBA-85EB-4642-A442-7B1D03773540Q24241232-74695D9B-80D4-407D-865C-D2AD623099E9Q24241947-E3F0CA1F-0EC2-4AA1-B705-39E5BE6E6FB8Q24242191-D0B2EBB1-870C-4281-B8AA-9A0703650867Q24242944-17753F6C-F09B-4BC2-94A0-B69CC69544BAQ24245014-6A5FB7E1-EDE9-48FF-AE5D-36B022B93FBDQ24245704-306A190F-FE4D-4475-8E6A-6AF66757EC21Q24289030-F53A5EB9-2FD0-4DF4-81F9-571D2F0047E7Q24310586-1DE5A3AF-EDE9-41CE-ABD1-9A631B85E9FDQ24630052-3E002DCE-D82A-433F-A6CC-20ACB6C24F1AQ24650811-466C6F77-3251-4095-B399-86CD69C0BBC4Q24652838-977B8A1D-1534-475F-A873-48D8B85CB311Q24655017-CB508D27-383E-4E4D-ABCB-D2FAEC77B8D3Q24657798-D58D6EF1-0D3F-434F-ACE5-68FE7FBC3BDAQ24681371-C93BD06A-9FB3-4A47-BD05-D394A71835A2Q24791473-AC58F4E4-076A-4AA9-A2F8-A209912487DBQ24792362-B71D82C3-711F-4FA5-B2D2-A26FAC3C17F2Q24792379-C3BEB732-9531-49EE-AE4B-3154909EAA5BQ24792450-79F129A8-C95A-41B3-91B7-7C1F74612B97Q24792532-3BE84651-7D45-41BE-913A-4103DB3DAA63Q24792591-551ABC82-D34D-46A5-8E98-ED9000845D77Q24792999-49AA4775-E2AC-456C-B651-9655AEC3F445Q24793271-DF793D06-764A-4915-B80C-2B7F9E8C35F1
P2860
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
description
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2000
@ast
im Januar 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 20 January 2000)
@en
wetenschappelijk artikel (gepubliceerd op 2000/01/20)
@nl
наукова стаття, опублікована в січні 2000
@uk
مقالة علمية (نشرت في 20-1-2000)
@ar
name
Effects of an angiotensin-conv ...... r events in high-risk patients
@ast
Effects of an angiotensin-conv ...... r events in high-risk patients
@en
type
label
Effects of an angiotensin-conv ...... r events in high-risk patients
@ast
Effects of an angiotensin-conv ...... r events in high-risk patients
@en
prefLabel
Effects of an angiotensin-conv ...... r events in high-risk patients
@ast
Effects of an angiotensin-conv ...... r events in high-risk patients
@en
P2093
P3181
P1476
Effects of an angiotensin-conv ...... r events in high-risk patients
@en
P2093
P304
P3181
P356
10.1056/NEJM200001203420301
P407
P577
2000-01-20T00:00:00Z